AlphaCore Capital’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.8M Buy
170,924
+6,556
+4% +$175K 0.11% 162
2025
Q4
$4.09M Buy
164,368
+30,025
+22% +$757K 0.09% 189
2025
Q3
$3.42M Buy
134,343
+46,820
+53% +$1.16M 0.12% 142
2025
Q2
$2.12M Buy
87,523
+17,316
+25% +$404K 0.08% 181
2025
Q1
$1.78M Buy
70,207
+10,012
+17% +$262K 0.15% 130
2024
Q4
$1.6M Buy
60,195
+4,973
+9% +$135K 0.35% 54
2024
Q3
$1.6M Buy
55,222
+625
+1% +$18.2K 0.36% 54
2024
Q2
$1.53M Sell
54,597
-17,223
-24% -$474K 0.37% 46
2024
Q1
$1.99M Sell
71,820
-1,153
-2% -$32K 0.53% 35
2023
Q4
$2.1M Buy
72,973
+10,410
+17% +$315K 0.31% 57
2023
Q3
$2.08M Buy
62,563
+2,457
+4% +$86.9K 0.33% 57
2023
Q2
$2.2M Buy
60,106
+33,831
+129% +$1.32M 0.35% 58
2023
Q1
$1.07M Buy
26,275
+650
+3% +$28.1K 0.28% 53
2022
Q4
$1.31M Buy
25,625
+1,708
+7% +$81.9K 0.51% 25
2022
Q3
$1.05M Buy
23,917
+4,422
+23% +$215K 0.48% 25
2022
Q2
$1.02M Buy
19,495
+2,973
+18% +$152K 0.47% 23
2022
Q1
$855K Buy
+16,522
New +$857K 0.33% 28
2020
Q2
Sell
-7,824
Closed -$242K 240
2020
Q1
$242K Hold
7,824
0.19% 42
2019
Q4
$291K Buy
+7,824
New +$279K 0.18% 53

Other funds holding PFE

AlphaCore Capital's PFE Position: Q1 2026 in Review

AlphaCore Capital increased its Pfizer (PFE) stake by 4% in Q1 2026, buying an estimated $175K and bringing the position to 170,924 shares worth $4.8M. The position accounts for 0.11% of the portfolio, ranked #162.

AlphaCore Capital first reported a position in PFE in Q4 2019 and has held it in 19 quarters since. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • AlphaCore Capital held 170,924 shares of Pfizer worth $4.8M as of Q1 2026.
  • AlphaCore Capital bought 6,556 Pfizer shares in Q1 2026, an estimated $175K.
  • Pfizer made up 0.11% of AlphaCore Capital's portfolio in Q1 2026, its #162 holding.
  • AlphaCore Capital first reported a position in Pfizer in Q4 2019 and has held it in 19 quarters since.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on AlphaCore Capital's 13F filing for Q1 2026, filed 15 May 2026.